AbClon Inc. (KOSDAQ:174900)

Market Cap	678.37B +229.9%
Revenue (ttm)	4.74B +104.5%
Net Income	-15.02B
EPS	-784.78
Shares Out	19.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	278,882
Open	33,850
Previous Close	34,000
Day's Range	30,500 - 33,850
52-Week Range	9,770 - 95,800
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 174900

Financial Performance

In 2025, AbClon's revenue was 4.71 billion, an increase of 101.47% compared to the previous year's 2.34 billion. Losses were -18.10 billion, 11.1% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 12, 2026

Data Sources Report a data error